By 2020, approximately 157 million adults and 31 million children will be living with allergic rhinitis across the markets covered in this report. While Datamonitor does not anticipate a marked increase in cases over the forecast period, there remains a large population who are not optimally treated due to low diagnosis rates. It is primarily the most severe cases captured in clinical settings.
Features and benefits
- Gain insight to market potential, including a robust 10-year epidemiology forecast of allergic prevalent cases.
- Understand the key epidemiologic risk factors associated with allergic rhinitis.
Prevalence rates for allergic rhinitis in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) range from 14% to 31%, but diagnosis rates for allergic rhinitis hover around only 30–40% for adults in the US and Europe.
Datamonitor estimates that there were approximately 150 million adult cases of allergic rhinitis in 2010. Nearly half of these prevalent adult cases are in the US.
The diagnosis rates in the US (31%) and the five major EU markets (France: 30%, Germany: 41%, Italy: 33%, Spain: 33%, the UK: 36%) are similar. It is interesting that Germany has the highest diagnosis rate as the prevalence rates in the country are among the lowest. This may indicate an increased awareness of allergic rhinitis in Germany.
Your key questions answered
- What are the most robust epidemiological studies for allergic rhinitis prevalence data?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure or risk factors affect the trend in prevalence allergic rhinitis cases?